Dan Horner takes a detailed look at the February 2021 RECOVERY tocilizumab preprint. The appraisal examines reported survival benefits alongside patient selection, incomplete follow-up, absolute versus relative effects and the uncertainties that remained behind the optimistic headlines.
Tocilizumabulous? A special offer on IL-6 with Tocilizumab. Read More
The first February 2021 report of RECOVERY’s tocilizumab results, written as the announcement and preprint emerged. Simon Carley and Dan Horner outline the reported benefits in hospitalised patients with hypoxia and inflammation, while flagging the need for fuller appraisal and questions about immunosuppression.
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s Read More
A January 2021 appraisal of REMAP-CAP’s early tocilizumab and sarilumab findings in critically ill patients with COVID-19. Dan Horner examines organ support and survival outcomes, strict eligibility criteria and the uncertainties that remained as the results moved rapidly into policy and public discussion.
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s Read More
Before the fuller tocilizumab trial reports, Dan Horner examined the conflicting evidence available in December 2020. This appraisal considers biological plausibility, early REMAP-CAP announcements, adverse effects and the difficulty of discussing an experimental treatment when media coverage runs ahead of the data.
Tocilizumaybe? Immune modulation in COVID-19 Read More
A September 2020 appraisal of REMAP-CAP’s hydrocortisone results in critically ill patients with COVID-19. Dan Horner and Simon Carley explain adaptive trials, Bayesian analysis and organ support outcomes, weighing the findings against early stopping, treatment crossover and the wider corticosteroid evidence.
The ‘Roid’ to Recovery? REMAP-CAP @ St Emlyn’s Read More
